GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

TAK-875

Company
Takeda
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00949091

    Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

    Not yet reported Takeda 60 participants Est. completion 2009-07 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01007097

    Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Takeda 426 participants Est. completion 2010-09 71 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01414920

    Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

    Not yet reported Takeda 368 participants Est. completion 2012-08 80 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01433393

    Double-blind Comparative Study of TAK-875

    Not yet reported Takeda 192 participants Est. completion 2012-09 19 sites Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01433406

    Long-term Study of TAK-875

    Not yet reported Takeda 1222 participants Est. completion 2013-12 71 sites Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01433419

    Open-label Study of TAK-875

    Not yet reported Takeda 333 participants Est. completion 2012-12 31 sites Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01456195

    Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

    Not yet reported Takeda 421 participants Est. completion 2013-07 95 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01481116

    Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

    Not yet reported Takeda 2454 participants Est. completion 2014-04 226 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01496443

    TAK-875 Glimepiride Drug-Interaction Study

    Not yet reported Takeda 28 participants Est. completion 2012-05 1 site Stand-alone
    Other conditions: Pharmacokinetics
    View official trial listing →
  • Terminated NCT NCT01549964

    Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

    Not yet reported Takeda 916 participants Est. completion 2014-03 160 sites Stand-alone
    Other conditions: Glycemic Control
    View official trial listing →
  • Completed NCT NCT01585792

    Double Blind Comparative Study of TAK-875

    Not yet reported Takeda 80 participants Est. completion 2012-12 2 sites Stand-alone
    Other conditions: Diabetic Patients
    View official trial listing →
  • Terminated NCT NCT01609582

    Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

    Not yet reported Takeda 3207 participants Est. completion 2014-05 584 sites Stand-alone
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Terminated NCT NCT01647542

    Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

    Not yet reported Takeda 393 participants Est. completion 2014-03 51 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01829464

    TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

    Not yet reported Takeda 90 participants Est. completion 2014-03 86 sites Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Terminated NCT NCT01829477

    Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

    Not yet reported Takeda 33 participants Est. completion 2014-02 69 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01834274

    Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

    Not yet reported Takeda 96 participants Est. completion 2014-03 104 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01982253

    Fasiglifam 25 mg BID vs 50 mg QD

    Not yet reported Takeda 10 participants Est. completion 2014-01 88 sites
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT02015780

    Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

    Not yet reported Takeda Est. completion 2016-01 30 sites
    Type 2 diabetesChronic kidney disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.